• Peroxidasin Drives GBM Progression by Regulating LDHA and Gl

  2026-05-26

  This study identifies peroxidasin (PXDN) as a critical modulator of glycolytic metabolism in glioblastoma, acting through regulation of lactate dehydrogenase A (LDHA). The findings highlight PXDN as a potential diagnostic marker and therapeutic target, offering new directions for metabolic intervention in GBM.

• Luminescent ATP Detection Assay Kit: Reliable ATP Quantifica

  2026-05-26

  This article guides biomedical researchers through common pitfalls in ATP measurement, focusing on the scientific reliability and workflow efficiency of the Luminescent ATP Detection Assay Kit (SKU K2040). By addressing real-world challenges from sample compatibility to data interpretation, it demonstrates how SKU K2040 advances energy metabolism studies and mitigates reproducibility issues across cell, tissue, and disease models.

• Outer Membrane Vesicle Display of mRNA Antigens for Tumor Va

  2026-05-25

  Li et al. have developed a rapid platform using bacteria-derived outer membrane vesicles (OMVs) engineered for surface display of mRNA antigens, enabling customizable and potent personalized tumor vaccines. This innovation addresses the limitations of lipid nanoparticles for mRNA delivery and demonstrates significant tumor suppression and immune memory in preclinical models.

• Nilotinib (AMN-107): Benchmarks for BCR-ABL and KIT Mutant I

  2026-05-25

  Nilotinib (AMN-107) is a selective tyrosine kinase inhibitor with high potency against BCR-ABL and KIT mutants, making it a key tool in chronic myeloid leukemia research. Rigorous in vitro and in vivo studies reveal nanomolar inhibition, robust antiproliferative effects, and defined solubility and storage profiles.

• Amitriptyline HCl in Lipidomics-Driven Neuropharmacology Res

  2026-05-24

  Discover how Amitriptyline HCl enables advanced studies of neurotransmitter receptor modulation and lipid metabolism in neuropharmacology research. This article uniquely explores its application in bridging neurotransmitter signaling and lipidomics, setting it apart from prior benchmarks.

• Sorafenib in Cancer Biology: Protocols, Innovations, and Pit

  2026-05-23

  Sorafenib (BAY-43-9006) is a multikinase inhibitor that enables high-impact cancer biology research by targeting Raf and VEGFR pathways. This guide details actionable protocols, advanced applications, and troubleshooting strategies, all contextualized by recent mechanistic breakthroughs and APExBIO’s high reagent standards.

• Luminescent ATP Detection Assay Kit: Unveiling Metabolic Rew

  2026-05-22

  Explore how the Luminescent ATP Detection Assay Kit enables precise cellular ATP quantification and empowers advanced metabolic research in cancer biology. This article uniquely connects assay performance with emerging insights into tumor energy metabolism.

• CBX2 Suppresses Tumor Immunogenicity via Noncanonical Comple

  2026-05-22

  The referenced study uncovers a novel mechanism by which CBX2, a polycomb group protein, dampens tumor immunogenicity and interferon signaling through a noncanonical corepressor complex with RACK1 and HDAC1. These findings provide new insight into immune evasion strategies in cancer and suggest CBX2 as a potential biomarker and therapeutic target for enhancing immunotherapy efficacy.

• Vitamin C (CAS 50-81-7): Advanced Organoid Applications in A

  2026-05-21

  Explore the advanced biomedical applications of Vitamin C (ascorbic acid) as an anticancer and antiviral agent, with a deep focus on organoid-based models and translational assay design. This article offers a unique, protocol-driven perspective on leveraging high-purity Vitamin C (CAS 50-81-7) in cutting-edge cancer and virology research.

• Pam3CSK4 TFA: Driving Translational Innovation in Maternal I

  2026-05-21

  This article explores how Pam3CSK4 TFA, a synthetic TLR1/2 agonist, advances translational immunology by enabling mechanistic dissection of maternal-neonatal immune responses—particularly in Group B Streptococcus (GBS) risk contexts. Integrating recent biomarker breakthroughs and strategic experimental guidance, we bridge the gap between bench and bedside, highlighting APExBIO's Pam3CSK4 TFA as a pivotal tool for next-generation risk stratification and protocol optimization.

• SP1/ADAM10/DRP1 Axis Drives SMC-EC Crosstalk in Hypoxic PH

  2026-05-20

  This study uncovers how the SP1/ADAM10/DRP1 signaling axis mediates the communication between endothelial and smooth muscle cells under hypoxia, advancing our understanding of pulmonary artery remodeling in hypoxia-induced pulmonary hypertension. The findings highlight potential molecular targets to disrupt pathogenic cell proliferation and apoptosis, with significant implications for therapeutic intervention.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-05-20

  Anlotinib hydrochloride stands out as a potent, selective multi-target tyrosine kinase inhibitor with robust anti-angiogenic activity, enabling highly reproducible endothelial cell and tumor angiogenesis assays. This guide delivers actionable protocol enhancements, troubleshooting strategies, and data-driven insights to help cancer researchers achieve superior experimental outcomes.

• 2X Taq PCR Master Mix (with dye): Advancing DNA Repair Assay

  2026-05-19

  Explore how 2X Taq PCR Master Mix (with dye) enables high-fidelity DNA repair and genotyping workflows. This article uniquely connects molecular biology assay optimization to recent advances in colorectal cancer research.

• ATRX-Deficient Glioma Cells: Enhanced Sensitivity to RTK and

  2026-05-19

  This study identifies that ATRX-deficient high-grade glioma cells are more susceptible to receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors, especially when combined with temozolomide. Incorporating ATRX mutation status into clinical trial analyses may improve therapeutic strategies for aggressive gliomas.

• Caspase-3 Colorimetric Assay Kit: Practical Workflow Guidanc

  2026-05-18

  The Caspase-3 Colorimetric Assay Kit enables reliable, quantitative measurement of DEVD-dependent caspase-3 activity in cell and tissue lysates, supporting apoptosis and neurodegenerative disease research. It streamlines caspase activity measurement with a simple colorimetric readout and defined protocol parameters. This kit is not suited for live-cell imaging or multiplexed high-throughput screening outside its validated workflow.

16647 records 1/1110 page Next 12345 下5页 Last page